$CBUS
Cibus, Inc.

2018 Q4 Form 10-Q Financial Statement

#000119312518325626 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q4 2018 Q3 2017 Q4
Revenue $2.000K $27.00K $186.0K
YoY Change -98.92% -38.64% 165.71%
Cost Of Revenue $0.00 $0.00 $0.00
YoY Change
Gross Profit $2.000K $27.00K $190.0K
YoY Change -98.95% -38.64% 171.43%
Gross Profit Margin 100.0% 100.0% 102.15%
Selling, General & Admin $6.280M $3.311M $4.600M
YoY Change 36.52% -49.47% 57.53%
% of Gross Profit 314000.0% 12262.96% 2421.05%
Research & Development $2.350M $3.440M $2.400M
YoY Change -2.08% -46.57% 38.73%
% of Gross Profit 117500.0% 12740.74% 1263.16%
Depreciation & Amortization $350.0K $356.0K $140.0K
YoY Change 150.0% 143.84% -50.0%
% of Gross Profit 17500.0% 1318.52% 73.68%
Operating Expenses $8.630M $7.726M $7.000M
YoY Change 23.29% -40.53% 50.86%
Operating Profit -$8.628M -$7.699M -$6.810M
YoY Change 26.7% -40.53% 49.02%
Interest Expense $160.0K $349.0K -$40.00K
YoY Change -500.0% 627.08% -300.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$8.470M -$7.483M -$6.850M
YoY Change 23.65% -42.01% 50.55%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.468M -$7.483M -$6.849M
YoY Change 23.64% -42.01% 50.53%
Net Earnings / Revenue -423400.0% -27714.81% -3682.26%
Basic Earnings Per Share
Diluted Earnings Per Share -$259.7K -$231.0K -$246.7K
COMMON SHARES
Basic Shares Outstanding 32.57M shares 32.35M shares 27.69M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q4 2018 Q3 2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $93.80M $101.8M $56.70M
YoY Change 65.43% 62.88% 1034.0%
Cash & Equivalents $93.79M $101.8M $56.66M
Short-Term Investments
Other Short-Term Assets $66.00K $1.100M $135.0K
YoY Change -51.11% 175.0% -55.0%
Inventory
Prepaid Expenses $893.0K $261.0K
Receivables $0.00 $0.00
Other Receivables $200.0K $200.0K
Total Short-Term Assets $95.52M $103.0M $57.46M
YoY Change 66.25% 63.3% 951.36%
LONG-TERM ASSETS
Property, Plant & Equipment $21.85M $21.31M $14.35M
YoY Change 52.23% 74.72% 30.55%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $306.0K $341.0K $357.0K
YoY Change -14.29% 7.57% 117.68%
Total Long-Term Assets $23.27M $21.65M $14.71M
YoY Change 58.18% 73.02% 31.83%
TOTAL ASSETS
Total Short-Term Assets $95.52M $103.0M $57.46M
Total Long-Term Assets $23.27M $21.65M $14.71M
Total Assets $118.8M $124.6M $72.17M
YoY Change 64.61% 64.91% 334.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $818.0K $1.240M $1.023M
YoY Change -20.04% 120.64% 186.55%
Accrued Expenses $2.007M $2.669M $449.0K
YoY Change 346.99% 319.65% 23.69%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $300.0K
YoY Change
Total Short-Term Liabilities $7.004M $6.869M $4.254M
YoY Change 64.65% 35.03% 48.48%
LONG-TERM LIABILITIES
Long-Term Debt $18.20M $17.40M $10.10M
YoY Change 80.2% 120.25%
Other Long-Term Liabilities $163.0K $100.0K $289.0K
YoY Change -43.6% -75.0% -51.83%
Total Long-Term Liabilities $163.0K $17.50M $289.0K
YoY Change -43.6% 110.84% -51.83%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.004M $6.869M $4.254M
Total Long-Term Liabilities $163.0K $17.50M $289.0K
Total Liabilities $25.39M $24.39M $14.69M
YoY Change 72.85% 81.21% 319.26%
SHAREHOLDERS EQUITY
Retained Earnings -$82.45M -$73.98M -$54.55M
YoY Change 51.14% 55.09% 90.94%
Common Stock $176.1M $174.2M $112.0M
YoY Change 57.17% 58.64% 168.73%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $93.40M $100.2M $57.48M
YoY Change
Total Liabilities & Shareholders Equity $118.8M $124.6M $72.17M
YoY Change 64.61% 64.91% 334.14%

Cashflow Statement

Concept 2018 Q4 2018 Q3 2017 Q4
OPERATING ACTIVITIES
Net Income -$8.468M -$7.483M -$6.849M
YoY Change 23.64% -42.01% 50.53%
Depreciation, Depletion And Amortization $350.0K $356.0K $140.0K
YoY Change 150.0% 143.84% -50.0%
Cash From Operating Activities -$6.650M -$4.770M -$6.820M
YoY Change -2.49% 149.74% -3.13%
INVESTING ACTIVITIES
Capital Expenditures -$1.020M -$330.0K $830.0K
YoY Change -222.89% -67.0% -477.27%
Acquisitions
YoY Change
Other Investing Activities $50.00K
YoY Change
Cash From Investing Activities -$970.0K -$330.0K $830.0K
YoY Change -216.87% -67.0% -477.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.060M 1.330M 100.0K
YoY Change 960.0% -97.89%
NET CHANGE
Cash From Operating Activities -6.650M -4.770M -6.820M
Cash From Investing Activities -970.0K -330.0K 830.0K
Cash From Financing Activities 1.060M 1.330M 100.0K
Net Change In Cash -6.560M -3.770M -5.890M
YoY Change 11.38% -106.28% -18.87%
FREE CASH FLOW
Cash From Operating Activities -$6.650M -$4.770M -$6.820M
Capital Expenditures -$1.020M -$330.0K $830.0K
Free Cash Flow -$5.630M -$4.440M -$7.650M
YoY Change -26.41% 387.91% 12.17%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
32572359 shares
CY2017Q3 us-gaap Lessee Finance Lease Renewal Term1
LesseeFinanceLeaseRenewalTerm1
P5Y
CY2017Q3 us-gaap Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
P20Y
CY2017Q3 clxt Number Of Lease Extension Options
NumberOfLeaseExtensionOptions
4 Options
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
62545000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62545000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2669000
CY2018Q3 us-gaap Assets Current
AssetsCurrent
102979000
CY2018Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1826000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
174206000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1240000
CY2018Q3 us-gaap Assets
Assets
124625000
CY2018Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
101796000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
101846000
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000 shares
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
32463407 shares
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
32463407 shares
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
3000
CY2018Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
7000
CY2018Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
91000
CY2018Q3 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1937000
CY2018Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1016000
CY2018Q3 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
166000
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
4100000
CY2018Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
17200000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6869000
CY2018Q3 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
413000
CY2018Q3 us-gaap Liabilities
Liabilities
24393000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
124625000
CY2018Q3 us-gaap Minimum Net Worth Required For Compliance
MinimumNetWorthRequiredForCompliance
300000000
CY2018Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
341000
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2018Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
21305000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
967000
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23131000
CY2018Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73977000
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
11429000
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1314939 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
7.01
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3140822 shares
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.14
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
17718000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
100232000
CY2018Q3 clxt Capital Leases Obligations And Financing Leases Noncurrent
CapitalLeasesObligationsAndFinancingLeasesNoncurrent
17433000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5026000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
893000
CY2017Q4 us-gaap Assets Current
AssetsCurrent
57457000
CY2017Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
3000
CY2017Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1283000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
112021000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1023000
CY2017Q4 us-gaap Assets
Assets
72167000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56664000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
56664000
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
275000000 shares
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
27718780 shares
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
27718780 shares
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2017Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
43000
CY2017Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
289000
CY2017Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
1350000
CY2017Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
945000
CY2017Q4 us-gaap Due From Related Parties Current
DueFromRelatedPartiesCurrent
167000
CY2017Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
10100000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4254000
CY2017Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
4000
CY2017Q4 us-gaap Liabilities
Liabilities
14691000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
72167000
CY2017Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
357000
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2017Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
14353000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000 shares
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
626000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
15636000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-54548000
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3883432 shares
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.16
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
49965000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
57476000
CY2017Q4 clxt Capital Leases Obligations And Financing Leases Noncurrent
CapitalLeasesObligationsAndFinancingLeasesNoncurrent
10148000
CY2017Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
3300000
CY2017Q3 us-gaap Expense Related To Distribution Or Servicing And Underwriting Fees
ExpenseRelatedToDistributionOrServicingAndUnderwritingFees
3100000
CY2017Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
58000000
CY2017Q3 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
7000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
57519000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
us-gaap Costs And Expenses
CostsAndExpenses
19298000
us-gaap Depreciation
Depreciation
414000
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
67000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1250000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
160000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
47000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.89
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
4000
us-gaap Interest Paid Net
InterestPaidNet
44000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1614000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
65101000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
46000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet
0
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-159000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19131000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
205000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
260000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-222000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-110000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5968000
us-gaap Net Income Loss
NetIncomeLoss
-19131000
us-gaap Operating Income Loss
OperatingIncomeLoss
-18976000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
195000
us-gaap Proceeds From Contributions From Parent
ProceedsFromContributionsFromParent
3000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1614000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3330000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
61292000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
182000
us-gaap Profit Loss
ProfitLoss
-19131000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9157000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
322000
us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
6957000
us-gaap Share Based Compensation
ShareBasedCompensation
9980000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.451 pure
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10141000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.2740 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0125 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0231 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1000000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
10200000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21615703 shares
clxt Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
2081000
clxt Interest Income
InterestIncome
93000
clxt Repayment Of Advances From Parent
RepaymentOfAdvancesFromParent
3000000
clxt Increase Decrease In Due To From Related Parties Current
IncreaseDecreaseInDueToFromRelatedPartiesCurrent
1534000
clxt Unrealized Transaction Gains Losses On Related Party Activity
UnrealizedTransactionGainsLossesOnRelatedPartyActivity
8000
dei Amendment Flag
AmendmentFlag
false
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3016000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
45182000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
us-gaap Costs And Expenses
CostsAndExpenses
19721000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Depreciation
Depreciation
727000
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2018
dei Document Type
DocumentType
10-Q
us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
104000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.65
us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
The Company provides a 401(k) defined contribution plan (the Plan) for participation by all regular fulltime employees who have completed three months of service.
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
dei Entity Central Index Key
EntityCentralIndexKey
0001705843
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y7M6D
dei Entity Registrant Name
EntityRegistrantName
CALYXT, INC.
dei Entity Small Business
EntitySmallBusiness
false
dei Document Period End Date
DocumentPeriodEndDate
2018-09-30
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
901000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Transfers Net
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationTransfersNet
0
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-30000
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19429000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
217000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
325000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-234000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1770000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
70000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
88000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
88000
us-gaap Interest Paid Net
InterestPaidNet
856000
us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
7300000
us-gaap Nature Of Operations
NatureOfOperations
<div> <table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" border="0" cellpadding="0" cellspacing="0" width="100%"> <tr style="page-break-inside:avoid"> <td width="4%" valign="top" align="left"><b>1.</b></td> <td align="left" valign="top"> <p style="margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;" align="left"><b>Nature of Business</b></p> </td> </tr> </table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Calyxt, Inc., formerly known as Cellectis Plant Sciences, Inc., was founded in 2010 and incorporated in Delaware. The Company is headquartered in Roseville, Minnesota. The Company is a consumer-centric, food- and agriculture-focused company. Prior to the Company&#x2019;s initial public offering (IPO) on July&#xA0;25, 2017, Calyxt was a wholly owned subsidiary of Cellectis. As of September&#xA0;30, 2018, Cellectis owned approximately 70.0% of the Company&#x2019;s outstanding common stock. Calyxt&#x2019;s common stock is listed on the Nasdaq market under the ticker symbol &#x201C;CLXT&#x201D;.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i>Initial Public Offering</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> On July&#xA0;25, 2017, the Company completed an IPO of its common stock. The Company sold an aggregate of 8,050,000 shares of common stock at a price of $8.00 per share, including 1,050,000 shares of common stock pursuant to the exercise of the underwriters&#x2019; option to purchase additional shares. In the aggregate, the Company received net proceeds from the IPO and exercise of the overallotment option of approximately $58.0&#xA0;million, after deducting underwriting discounts and commissions of $3.1&#xA0;million and offering expenses totaling approximately $3.3&#xA0;million. As part of the IPO, Cellectis purchased 2,500,000 shares of common stock for a value of $20.0&#xA0;million, the proceeds of which are included in the net proceeds of approximately $58.0&#xA0;million. The Company used $5.7&#xA0;million of the proceeds from Cellectis to pay a portion of the outstanding obligations owed to Cellectis.</p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> <b><i><font style="white-space:nowrap">Follow-on</font> Public Offering</i></b></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> On May&#xA0;22, 2018, the Company completed a <font style="white-space:nowrap">follow-on</font> offering of its common stock. The Company sold an aggregate of 4,057,500 shares of common stock at a price of $15.00 per share, including 457,500 shares of common stock pursuant to the exercise of the underwriters&#x2019; option to purchase additional shares. In the aggregate, the Company received net proceeds from the <font style="white-space:nowrap">follow-on</font> offering and exercise of the overallotment option of approximately $57.0&#xA0;million, after deducting underwriting discounts and commissions of $3.2&#xA0;million and offering expenses totaling approximately $0.7&#xA0;million. As part of the <font style="white-space:nowrap">follow-on</font> offering, Cellectis purchased 550,000 shares of common stock for a value of $8.3&#xA0;million, the proceeds of which are included in the net proceeds of approximately $57.0&#xA0;million.</p> </div>
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-830000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
59612000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13600000
us-gaap Net Income Loss
NetIncomeLoss
-19429000
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segment
us-gaap Operating Income Loss
OperatingIncomeLoss
-19487000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
154000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
830000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
222000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
57706000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2128000
us-gaap Profit Loss
ProfitLoss
-19429000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7493000
us-gaap Sale Leaseback Transaction Date
SaleLeasebackTransactionDate
2017-09-06
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
234000
us-gaap Share Based Compensation
ShareBasedCompensation
3016000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.572 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
4.62
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
57041000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2128000
clxt Increase Decrease In Due To From Related Parties Current
IncreaseDecreaseInDueToFromRelatedPartiesCurrent
576000
clxt Property And Equipment Included In Financing Lease Obligation
PropertyAndEquipmentIncludedInFinancingLeaseObligation
6849000
clxt Unrealized Transaction Gains Losses On Related Party Activity
UnrealizedTransactionGainsLossesOnRelatedPartyActivity
-12000
clxt Operating Leases Expiration Date
OperatingLeasesExpirationDate
2018-06
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
12228000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.4086 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0218 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
576853 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0282 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
6416000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
295443 shares
dei Trading Symbol
TradingSymbol
CLXT
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
12.42
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
18.84
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2500000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
461200 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of Estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, including those related to stock-based compensation and the valuation allowance for deferred tax assets and derivatives. The Company bases its estimates on historical experience and on various other market-specific and relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p> </div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
30040926 shares
clxt Stock Issuance Costs Incurred During Noncash Or Partial Noncash Transaction
StockIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction
443000
clxt Interest Income
InterestIncome
989000
CY2017 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.35 pure
CY2017 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
1600000
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y9M18D
CY2018Q2 us-gaap Sale Leaseback Transaction Annual Rental Payments
SaleLeasebackTransactionAnnualRentalPayments
1400000
CY2018Q2 us-gaap Sale Leaseback Transaction Rent Expense
SaleLeasebackTransactionRentExpense
490000
CY2017Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
CY2017Q3 us-gaap Costs And Expenses
CostsAndExpenses
12991000
CY2017Q3 us-gaap Depreciation
Depreciation
146000
CY2017Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
22000
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
CY2017Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
3000
CY2017Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-5000
CY2017Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2017Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-12904000
CY2017Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
90000
CY2017Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
48000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-12904000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12947000
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
65000
CY2017Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6438000
CY2017Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
44000
CY2017Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
6553000
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25531572 shares
CY2017Q3 clxt Interest Income
InterestIncome
93000
CY2018Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
0
CY2018Q3 us-gaap Costs And Expenses
CostsAndExpenses
7726000
CY2018Q3 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Percent
DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
0.03 pure
CY2018Q3 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1.00 pure
CY2018Q3 us-gaap Depreciation
Depreciation
356000
CY2018Q3 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
28000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2018Q3 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
349000
CY2018Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-12000
CY2018Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7483000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
229000
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
228000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-7483000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7699000
CY2018Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
0
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3307000
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
27000
CY2018Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4419000
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
32381010 shares
CY2018Q3 clxt Interest Income
InterestIncome
578000
CY2018Q3 clxt Defined Contribution Plan Additional Matching Contribution Percent Of Match
DefinedContributionPlanAdditionalMatchingContributionPercentOfMatch
0.50 pure

Files In Submission

Name View Source Status
0001193125-18-325626-index-headers.html Edgar Link pending
0001193125-18-325626-index.html Edgar Link pending
0001193125-18-325626.txt Edgar Link pending
0001193125-18-325626-xbrl.zip Edgar Link pending
clxt-20180930.xml Edgar Link completed
clxt-20180930.xsd Edgar Link pending
clxt-20180930_cal.xml Edgar Link unprocessable
clxt-20180930_def.xml Edgar Link unprocessable
clxt-20180930_lab.xml Edgar Link unprocessable
clxt-20180930_pre.xml Edgar Link unprocessable
d634605d10q.htm Edgar Link pending
d634605dex311.htm Edgar Link pending
d634605dex312.htm Edgar Link pending
d634605dex32.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending